MARKET

LXEO

LXEO

Lexeo Therapeutics Inc
NASDAQ
6.57
-0.22
-3.24%
Closed 16:18 02/12 EST
OPEN
6.84
PREV CLOSE
6.79
HIGH
6.93
LOW
6.39
VOLUME
527.09K
TURNOVER
0
52 WEEK HIGH
10.99
52 WEEK LOW
1.450
MARKET CAP
479.53M
P/E (TTM)
-2.4321
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LXEO last week (0202-0206)?
Weekly Report · 3d ago
Lexeo Therapeutics Announces Head of Research Transition
TipRanks · 02/05 22:04
Lexeo Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Narinder Pal Bhalla
Reuters · 02/05 21:46
Lexeo Therapeutics Announces Transition Compensation Agreement for Dr. Adler
Reuters · 02/05 21:18
Lexeo Therapeutics to Present at Guggenheim Biotech Summit and Oppenheimer Healthcare Conference
Reuters · 02/05 12:30
Weekly Report: what happened at LXEO last week (0126-0130)?
Weekly Report · 02/02 10:19
BUZZ-U.S. STOCKS ON THE MOVE-Sysco, Corning, HCA Healthcare
Reuters · 01/27 15:45
BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare
Reuters · 01/27 14:06
More
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Webull offers Lexeo Therapeutics Inc stock information, including NASDAQ: LXEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXEO stock methods without spending real money on the virtual paper trading platform.